Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
Results reinforce commitment to next-generation oral SERD development programme
The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
NABH shall encourage and provide assistance in onboarding their accredited/certified facilities on ABDM’s Health Facility Registry
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Subscribe To Our Newsletter & Stay Updated
